We therefore rationalised that inhibition of STAT3 using the clinically approved JAK2 inhibitor ruxolitinib may synergise with cisplatin in inducing cell death in HPV+ cervical cancer cells. The gene discussed is JAK2; the disease is cervical carcinoma.